Additionally, we explored its mechanism of action from the perspective of GVU and compared it with the use of PDGFRβ inhibitor to validate our hypothesis, providing a more possible theoretical basis for the treatment of VD with moxibustion in clinical practice. Here, PDGFRB is linked to sexually transmitted disease.